Disclosures and Conflict of Interest (COI) Mitigation

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose:

- Bethany Anderson, MD,
- Yee Chung Cheng, MD,
- Adrienne Cobb, MD, MS,
- William Gradishar, MD, FACP, FASCO
- Kurt Oettel, MD
- Marina Sharifi, MD
- The staffs of Wisconsin Association of Hematology and Oncology and Physicians' Education Resource®, LLC

Faculty	Grant/Research	Consultant	Speakers'	Shareholder	Other
	Support		Bureau		
		Novartis,			
		Lilly, Pfizer,			
		Puma,			
		Seagen,			
Ruth O'Regan, MD	Puma, Novartis	Astrazeneca			Gilead (DSMB)
					Site PI of clinical
					trial: Pfizer,
					Novartis,
					AstraZeneca,
		Novartis,			Genentech/Roche,
	Pfizer, Novartis,	Pfizer, Sanofi,			Sanofi, Context,
Kari Braun Wisinski,	Context	Stemline			Zymeworks,
MD	Therapeutics	Therapeutics			Seagen, Relay
	Context				
	Therapeutics-				
Sailaja Kamaraju, MD,	SMILE study for a				
MS	clinical trial				

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.